These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 15276088)

  • 1. Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3).
    Curtis JP; Alexander JH; Huang Y; Wallentin L; Verheugt FW; Armstrong PW; Krumholz HM; Van de Werf F; Danays T; Cheeks M; Granger CB;
    Am J Cardiol; 2004 Aug; 94(3):279-83. PubMed ID: 15276088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction.
    Wallentin L; Goldstein P; Armstrong PW; Granger CB; Adgey AA; Arntz HR; Bogaerts K; Danays T; Lindahl B; Mäkijärvi M; Verheugt F; Van de Werf F
    Circulation; 2003 Jul; 108(2):135-42. PubMed ID: 12847070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction.
    Sinnaeve PR; Alexander JH; Bogaerts K; Belmans A; Wallentin L; Armstrong P; Adgey JA; Tendera M; Diaz R; Soares-Piegas L; Vahanian A; Granger CB; Van De Werf FJ
    Am Heart J; 2004 Jun; 147(6):993-8. PubMed ID: 15199346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage.
    Giugliano RP; McCabe CH; Antman EM; Cannon CP; Van de Werf F; Wilcox RG; Braunwald E;
    Am Heart J; 2001 May; 141(5):742-50. PubMed ID: 11320361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.
    Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators
    Lancet; 2001 Aug; 358(9282):605-13. PubMed ID: 11530146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction.
    Kaul P; Armstrong PW; Cowper PA; Eisenstein EL; Granger CB; Van de Werf F; Mark DB
    Am Heart J; 2005 Apr; 149(4):637-44. PubMed ID: 15990746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of unfractionated heparin and a low-molecular-weight heparin following thrombolytic therapy for acute ST-segment elevation myocardial infarction.
    Wang XK; Zhang Y; Yang CM; Wang Y; Liu GY
    Clin Drug Investig; 2006; 26(6):341-9. PubMed ID: 17163268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction.
    Dunn CJ; Goa KL
    Am J Cardiovasc Drugs; 2001; 1(1):51-66. PubMed ID: 14728052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data.
    Armstrong PW; Chang WC; Wallentin L; Goldstein P; Granger CB; Bogaerts K; Danays T; Van de Werf F;
    CMAJ; 2006 May; 174(10):1421-6. PubMed ID: 16682709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial.
    ; Van De Werf F; Adgey J; Ardissino D; Armstrong PW; Aylward P; Barbash G; Betriu A; Binbrek AS; Califf R; Diaz R; Fanebust R; Fox K; Granger C; Heikkilä J; Husted S; Jansky P; Langer A; Lupi E; Maseri A; Meyer J; Mlczoch J; Mocceti D; Myburgh D; Oto A; Paolasso E; Pehrsson K; Seabra-Gomes R; Soares-Piegas L; Sùgrue D; Tendera M; Topol E; Toutouzas P; Vahanian A; Verheugt F; Wallentin L; White H
    Lancet; 1999 Aug; 354(9180):716-22. PubMed ID: 10475182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction.
    Sinnaeve P; Alexander J; Belmans A; Bogaerts K; Langer A; Diaz R; Ardissino D; Vahanian A; Pehrsson K; Armstrong P; Van de Werf F;
    Am Heart J; 2003 Jul; 146(1):27-32. PubMed ID: 12851604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators.
    Cannon CP; Gibson CM; McCabe CH; Adgey AA; Schweiger MJ; Sequeira RF; Grollier G; Giugliano RP; Frey M; Mueller HS; Steingart RM; Weaver WD; Van de Werf F; Braunwald E
    Circulation; 1998 Dec 22-29; 98(25):2805-14. PubMed ID: 9860780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
    Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM
    JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes.
    Mehta RH; Alexander JH; Van de Werf F; Armstrong PW; Pieper KS; Garg J; Califf RM; Granger CB
    JAMA; 2005 Apr; 293(14):1746-50. PubMed ID: 15827313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of the weight-adjusted dosing regimen of tenecteplase in the ASSENT-Trial.
    Angeja BG; Alexander JH; Chin R; Li X; Barron HV; Armstrong PW; Granger CB; Van de Werf F; Gibson CM
    Am J Cardiol; 2001 Dec; 88(11):1240-5. PubMed ID: 11728350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous enoxaparin following thrombolysis and intravenous unfractionated heparin in ST-elevation acute myocardial infarction: safety and efficacy of low vs full dose.
    Rubboli A; Gatti C; Spinolo L; Parollo R; Spitali G; Maresta A
    Minerva Cardioangiol; 2006 Feb; 54(1):131-7. PubMed ID: 16467747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS.
    Sinnaeve PR; Huang Y; Bogaerts K; Vahanian A; Adgey J; Armstrong PW; Wallentin L; Van de Werf FJ; Granger CB;
    Am Heart J; 2006 Oct; 152(4):684.e1-9. PubMed ID: 16996833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA.
    Van de Werf F; Barron HV; Armstrong PW; Granger CB; Berioli S; Barbash G; Pehrsson K; Verheugt FW; Meyer J; Betriu A; Califf RM; Li X; Fox NL;
    Eur Heart J; 2001 Dec; 22(24):2253-61. PubMed ID: 11728145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators.
    Antman EM; Gibson CM; de Lemos JA; Giugliano RP; McCabe CH; Coussement P; Menown I; Nienaber CA; Rehders TC; Frey MJ; Van der Wieken R; Andresen D; Scherer J; Anderson K; Van de Werf F; Braunwald E
    Eur Heart J; 2000 Dec; 21(23):1944-53. PubMed ID: 11071800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials.
    De Luca G; Marino P
    Am Heart J; 2007 Dec; 154(6):1085.e1-6. PubMed ID: 18035079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.